SOUTH SAN FRANCISCO, Calif., April 11, 2019 /PRNewswire/ -- Profusa, an empowered health company that is pioneering the next generation of personalized medicine, has expanded its leadership team to further the company's ability to transform the health and well-being of patients worldwide. The new hires include David (Dave) Icke as Head of Digital Health Business, Sean Givens as Head of Government Business and Hesham Younis, PhD, as Head of Business Development. All three will report directly to Ben Hwang, PhD, Chairman and CEO.
"I am thrilled to welcome Dave, Sean and Hesham to join our team at such an inflection point in the company's journey as we continue to scale and prepare for the future applications of our innovative biosensor technology," said Ben Hwang, PhD, CEO and Chairman of Profusa. "Each of them will help bring us one step closer to expanding the number of people who can benefit from Profusa's technology, solidifying our presence across the digital health and government ecosystems."
Icke brings 20 years of strong leadership experience, a proven entrepreneurial track record and deep technology and digital health expertise to his new role at Profusa. He will lead the architecture, development and commercialization of insight-driven solutions and partnerships enabled by continuous body chemistry data. Prior to joining Profusa, Icke led the Digital Health Business Unit at Becton Dickinson (BD), where he focused on consumer-centric digital solutions outside the hospital, including chronic disease management.
Givens comes to Profusa with over 20 years of government, accounting and contracting experience which he will leverage to deepen the company's government relations efforts. Most recently, Givens was co-founder and COO of MIODx, a company focused on immune repertoire profiling to predict patient response to immunotherapy regimens.
Younis, a 20-year industry veteran, will be responsible for driving partnerships, licensing and M&A activities to accelerate the number of people who can benefit from Profusa's technology and to grow commercialization potential across all markets. Prior to taking this role, Younis was VP of Marketing at Cardinal Health, the Global Head of Marketing for "hospital to home" at Philips and held various commercial and product leadership roles at GE Healthcare during his 10-year tenure there.
"Profusa is at such an exciting point of innovation and growth and I could not be more excited to join the team as we further our mission of making healthcare a proactive, collaborative and informed experience," said David (Dave) Icke, Head of Digital Health Business. "I look forward to growing our digital health footprint and bringing our technology into the hands of as many people as we can, enabling them to own, understand and make proactive decisions about their own health."
The addition of Icke, Givens and Younis to the Profusa team will help continue building the company's momentum and growth. In February, Profusa was named one of FierceMedTech's "Fierce 15" companies to watch, designating it as one of the most promising private med tech companies in the industry. In addition, Profusa presented promising clinical data this January from two studies evaluating the company's Lumee™ Oxygen Platform, a tiny, injectable tissue-integrated biosensor and an intelligent data platform intended for continuous, real-time monitoring of tissue oxygen levels, during the Leipzig Interventional Course (LINC) in Leipzig, Germany.
Founded in San Francisco, Calif., Profusa is an empowered health company led by visionary scientific founders, an experienced management team and a world-class board of directors who share the long-term goal of improving health and well-being for patients worldwide. With its long-lasting, injectable and affordable biosensors and its intelligent data platform, Profusa aims to provide people with a personalized biochemical signature rooted in data that clinicians trust and rely upon. These data may allow people to act as an active and educated participant alongside their care team and understand how their choices and decisions impact health and well-being, day-in and day-out. For more, visit https://profusa.com.
About the Lumee™ Oxygen Platform
Profusa's first clinical offering, the Lumee™ Oxygen Platform, which is CE marked for use in the European Union, is indicated for use in patients with potential acute and/or chronic changes in tissue oxygen levels who may benefit from monitoring. The sensors provide continuous and long-term monitoring of the oxygen in subcutaneous tissue. After a single injection, measurement thereafter are obtained non-invasively. In contrast to external pulse oximeters which measure oxygen bound to the hemoglobin in larger blood vessels, the Lumee™ platform measures dissolved oxygen at the tissue level in the fluid that bathes our cells.
SOURCE Profusa, Inc.